EUVIMEDEUVIMED entdecken
Crossref

Elevated liver enzymes at the time of deceased donor organ donation do not affect recipient or pancreas allograft survival following pancreas transplantation

Evan M Sood, Fernando Bomfim, Abbigail Delmonte, Kendall DeSantis, Rosy James, Naoru Koizumi, Robert Plews, Jorge Ortiz

HPB · 2024

DOI: 10.1016/j.hpb.2024.04.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HPB, 2024. Verfasst von Evan M Sood und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jacobs School of Medicine and Biomedical Sciences at University at Buffalo, 955 Main St, Buffalo, NY, 14203, USA. Hauptthemen laut MEDLINE: Pancreas Transplantation, Graft Survival, Bilirubin, Liver Function Tests. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There is a lack of data on the impact of donor liver function tests (LFTs) on pancreas transplantation outcomes. Understanding their contribution could expand the donor pool. METHODS: Using the UNOS database, data from January 2010-2022 was retrospectively analyzed. Multivariable cox regressions were performed to evaluate the association between LFTs (AST, ALT and total bilirubin levels), graft failure and mortality up to three years post-transplant. RESULTS: 9138 pancreas transplants were completed. Multivariate analysis showed no association between donor AST values > 500 U/L and increased rates of graft failure (p = 0.826) or mortality (p = 0.836). Similar findings were noted for donor ALT values > 500 U/L (p = 0.522 and p = 0.997, respectively). There was no correlation with graft failure (p = 0.322) or mortality (p = 0.423) for total bilirubin levels >3 mg/dL. CONCLUSION: LFTs in the deceased pancreas donor did not increase risk of graft failure or mortality following pancreas transplantation. Elevated LFTs should not serve as absolute contraindications to transplant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreas TransplantationGraft SurvivalBilirubinLiver Function TestsHumansRetrospective StudiesMaleFemaleAdultMiddle AgedRisk FactorsTime FactorsTissue DonorsDatabases, FactualTreatment OutcomeAlanine TransaminaseAspartate AminotransferasesBiomarkersDonor SelectionAllograftsRisk AssessmentUp-RegulationLiverPredictive Value of Tests

Substanzen

BilirubinAlanine TransaminaseAspartate AminotransferasesBiomarkers

Autor:innen und Institutionen

  • Jacobs School of Medicine and Biomedical Sciences at University at Buffalo, 955 Main St, Buffalo, NY, 14203, USA.
  • George Mason University, 4400 University Dr, Fairfax, VA, 22030, USA.
  • Department of Surgery, University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH, 45267, USA.
  • Department of Surgery, Erie County Medical Center, 462 Grider St, Buffalo, NY, 14215, USA. Electronic address: jortiz22@buffalo.edu.

Zitieren

APA

Sood, E. M., Bomfim, F., Delmonte, A., DeSantis, K., James, R., Koizumi, N., Plews, R., & Ortiz, J. (2024). Elevated liver enzymes at the time of deceased donor organ donation do not affect recipient or pancreas allograft survival following pancreas transplantation. HPB. https://doi.org/10.1016/j.hpb.2024.04.012

Vancouver

Sood EM, Bomfim F, Delmonte A, DeSantis K, James R, Koizumi N, et al. Elevated liver enzymes at the time of deceased donor organ donation do not affect recipient or pancreas allograft survival following pancreas transplantation. HPB. 2024. doi:10.1016/j.hpb.2024.04.012

BibTeX
@article{Sood2024,
  author = {Sood, Evan M and Bomfim, Fernando and Delmonte, Abbigail and DeSantis, Kendall and James, Rosy and Koizumi, Naoru and Plews, Robert and Ortiz, Jorge},
  title = {Elevated liver enzymes at the time of deceased donor organ donation do not affect recipient or pancreas allograft survival following pancreas transplantation},
  journal = {HPB},
  year = {2024},
  doi = {10.1016/j.hpb.2024.04.012}
}
Kostenlos starten →